$QNRX Balance Sheet | Understand Stock

$QNRX

$4.05 +$0.04 (1.0%) Close

$QNRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q4 FY2017 As of Dec 31, 2017
Cash and cash equivalents
USD
Total cash and cash equivalents
Marketable securities
Other receivables
USD
Total other receivables
Current assets
USD
Total current assets
Restricted cash
USD
Total restricted cash
Right of use - Assets under operating lease
Other Long-term receivables
USD
Total other Long-term receivables
Property, plant and equipment, net
USD
Total property, plant and equipment, net
Non-current assets
USD
Total non-current assets
Assets
USD
Total Assets
Trade payables
USD
Total trade payables
Leases liabilities
Other payables
USD
Total other payables
Current liabilities
USD
Total current liabilities
Warrants to ADS
USD
Total warrants to ADS
Non-current liabilities
ASSETS
Current assets:
Cash and cash equivalents
Deferred offering costs
Investments
Prepaid expenses and other current assets
Total current assets
Prepaid expenses - long term
Intangible assets, net
Other assets
Total assets

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable
Accrued expenses
Accrued license acquisition
Due to officers
Convertible notes payable
Warrant liability
Accrued interest and financing expense
Due to officers - short term
Total current liabilities
Due to officers - long term
Total liabilities

Shareholders' equity:
Share-based payments
USD
Total share-based payments
Treasury shares
USD
Total treasury shares
Equity
USD
Total equity
Ordinary shares, no par value per share, 5,000,000,000 authorized at June 30, 2026 and December 31, 2025, respectively - 70,294,615 (2,008,418 ADS's) ordinary shares issued and outstanding at June 30, 2026 and 52,441,360 (1,498,325 ADS's) ordinary shares issued and outstanding at December 31, 2025
ADS
Total ordinary shares, no par value per share, 5,000,000,000 authorized at June 30, 2026 and December 31, 2025, respectively - 70,294,615 (2,008,418 ADS's) ordinary shares issued and outstanding at June 30, 2026 and 52,441,360 (1,498,325 ADS's) ordinary shares issued and outstanding at December 31, 2025

Treasury stock, -0- ordinary shares issued at December 31, 2023 and 45 ordinary shares issued at December 31, 2022
Accumulated other comprehensive loss
Additional paid in capital
USD
Total additional paid in capital

Accumulated deficit
USD
Total accumulated deficit

Total shareholders' equity
Liabilities and shareholders' equity
USD
Total liabilities and shareholders' equity

Comments